Compare Eli Lilly And Co (LLY) vs Omnicom Group Inc. (OMC) Price & Performance

Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.

Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.

Omnicom Group (OMC) trades at $85.45, up 0.95% with a bullish technical outlook and strong institutional support. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q4 2025 and Q2 2026 missing expectations. Recent acquisition of Interpublic Group has driven 6.1% organic revenue growth and margin expansion, though 2025 saw a net loss of $54.5 million. Analyst consensus price target stands at $107 with 32% buy ratings.

OMC presents a value opportunity with attractive valuation metrics (P/S 0.97) and 4% dividend yield, supported by post-merger synergies and strong cash flow generation. Key risks include integration challenges from the Interpublic acquisition, competitive pressures in advertising services, and debt levels following the merger. The stock's current price offers 25% upside to consensus targets with institutional accumulation signaling confidence in the growth trajectory.